2020
Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials (1212)
Levin M, Buse D, Blumenfeld A, Lipton R, Stock E, Thiry A, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials (1212). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1212.Peer-Reviewed Original ResearchRimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials (2091)
Pavlovic J, Dodick D, Newman L, Lipton R, Stock E, Thiry A, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials (2091). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2091.Peer-Reviewed Original ResearchRimegepant 75 mg Is More Effective for Migraine Than Nonsteroidal Anti-inflammatory Drugs: Post Hoc Analysis of Data From 2 Phase 3 Trials (2107)
Turner I, Buse D, Blumenfeld A, Stock E, Stock D, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant 75 mg Is More Effective for Migraine Than Nonsteroidal Anti-inflammatory Drugs: Post Hoc Analysis of Data From 2 Phase 3 Trials (2107). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2107.Peer-Reviewed Original ResearchRimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine (2402)
McAllister P, Berman G, Kudrow D, Smith T, Lipton R, Stock E, Stock D, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine (2402). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2402.Peer-Reviewed Original Research
2019
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet 2019, 394: 737-745. PMID: 31311674, DOI: 10.1016/s0140-6736(19)31606-x.Peer-Reviewed Original ResearchConceptsAcute treatmentAdverse eventsBothersome symptomsH postdoseMigraine attacksSmall-molecule calcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptor antagonistInteractive web response systemMulticentre phase 3 trialSevere pain intensitySingle migraine attackCommon adverse eventsPlacebo-controlled trialSerious adverse eventsPhase 3 trialTreatment group assignmentWeb response systemUrinary tract infectionPeptide receptor antagonistHistory of migraineStandard tablet formulationModified intentionStudy medicationTreat populationCoprimary endpointsRimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. New England Journal Of Medicine 2019, 381: 142-149. PMID: 31291516, DOI: 10.1056/nejmoa1811090.Peer-Reviewed Original ResearchConceptsPercentage of patientsPeptide receptor antagonistPlacebo groupMigraine attacksBothersome symptomsReceptor antagonistCalcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptorGene-related peptide receptorOral Calcitonin GeneSingle migraine attackAcute migraine treatmentCommon adverse eventsPrimary end pointPhase 3 trialUrinary tract infectionOverall mean agePathogenesis of migraineModified intentionAdverse eventsTract infectionsTreat analysisMean ageMigraine treatmentCalcitonin gene